I hate to re-post something, but every now and then I'd rather put it here, so it doesn't get buried in a bunch of childish banter. This... regarding generative AI and potential problems going forward: __________________ One of the biggest issues going forward will be the use of generative AI that has derived its results from existing intellectual property. Artists' rights is going to become a HUGE issue. Last month when I said Accenture was oversold at $330, and it is about 8% below that level now.... was based on my premise that huge quagmires (and hundreds of large lawsuits based on the unlicensed use of IP) is looming large going forward. I couldn't think of a company that profits off of this kind of tumultuous environment, so ACN was my best guess. When I saw it was down that much, I figured that might be the play. Either way, if anyone has a company that profits off of guiding Fortune 500 companies thru the minefields of avoiding major litigation, it might be worth a look going forward because I really think this is gonna be a big thing in the not too distant future. And the consulting companies that deal with this stuff, will see top-line revenue grow over the next several years, because it is going to become a major issue. ~vz
$25 now.... still a good price. These are GREAT numbers. _________________________ “We were pleased to beat on our top and bottom lines, as we delivered another quarter of strong profits and record engagement,” said Jeff Tangney, co-founder and CEO of Doximity. “We’re proud to bring AI and automation to clinical workflows, with over 580,000 unique providers using our workflow tools last quarter.” Fiscal 2024 Fourth Quarter Financial Highlights All comparisons, unless otherwise noted, are to the three months ended March 31, 2023. Revenue: Revenue of $118.1 million, versus $111.0 million, an increase of 6% year-over-year. Subscription revenue of $112.7 million, versus $103.2 million, an increase of 9% year-over-year. Net income and non-GAAP net income: Net income of $40.6 million, versus $30.7 million, representing a margin of 34.4%, versus 27.6%. Non-GAAP net income of $51.0 million, versus $42.1 million, representing a margin of 43.2%, versus 38.0%. Adjusted EBITDA: Adjusted EBITDA of $56.4 million, versus $48.9 million, an increase of 15% year-over-year, representing adjusted EBITDA margins of 47.8%, versus 44.1%. Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.20, versus $0.14, while non-GAAP diluted net income per share was $0.25, versus $0.20. Operating cash flow and free cash flow: Operating cash flow of $63.9 million, versus $46.6 million, an increase of 37% year-over-year, and free cash flow of $62.3 million, versus $45.6 million, an increase of 37% year-over-year. Fiscal Year 2024 Financial Highlights All comparisons, unless otherwise noted, are to the fiscal year ended March 31, 2023. Revenue: Revenue of $475.4 million, versus $419.1 million, an increase of 13% year-over-year. Subscription revenue of $450.1 million, versus $389.7 million, an increase of 15% year-over-year. Net income and non-GAAP net income: Net income of $147.6 million, versus $112.8 million, representing a margin of 31.0%, versus 26.9%. Non-GAAP net income of $195.6 million, versus $154.9 million, representing a margin of 41.2%, versus 37.0%. Adjusted EBITDA: Adjusted EBITDA of $230.5 million, versus $184.0 million, an increase of 25% year-over-year, representing adjusted EBITDA margins of 48.5%, versus 43.9%. Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.72, versus $0.53, while non-GAAP diluted net income per share was $0.95, versus $0.73. Operating cash flow and free cash flow: Operating cash flow of $184.1 million, versus $179.6 million, an increase of 3% year-over-year, and free cash flow of $178.3 million, versus $173.4 million, an increase of 3% year-over-year. Financial Outlook Doximity is providing guidance for its fiscal first quarter ending June 30, 2024 as follows: Revenue between $119.5 million and $120.5 million. Adjusted EBITDA between $55 million and $56 million. Doximity is providing guidance for its fiscal year ending March 31, 2025 as follows: Revenue between $506 million and $518 million. Adjusted EBITDA between $238 million and $250 million. Stock Repurchase Program On May 1, 2024 the Company’s board of directors authorized a program to repurchase up to $500 million of the Company’s Class A common stock.(!!!!) The repurchase program has no expiration date and is subject to general business and market conditions and other investment opportunities, through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans. Immediately upon the repurchase of any shares of Class A common stock, such shares shall be retired by the Company and shall automatically return to the status of authorized but unissued shares of Class A common stock. All prior repurchase programs were completed as of April 2024.
Well $DOCS closed the ah's session at $27.48. Hard to chase a stock that jumped that much, but look at those margins. And they even got better. Subscription revenue on the rise too. AND... a $500M buyback initiated. ----> All that, and no debt on the books. I dunno, but as tech stocks go, this one is a gem imo. The 52 week high is $36. I have a feeling it's gonna continue up tomorrow. But as always, do your own dd.
Great call Van I missed it as it moved up too fast for me. Also, thanks for feedback on $BOIL hitting near $20. Your nonstop hit streak continues and I’m witness to it
I only paper trade though. (I wish someone would tell that to my email service.... @Protonmail.... they keep tellin' me my box has exceeded its limits and I need to pony up and send some money. 20 round trips per day generates a lot of confirmations over the space of a few months.) When is Stoney gonna take me up on my portfolio challenge?
Well, it hit $140 today. 40% in a month. I'm not saying charts never lie, because they do, all the time.... but I did feel pretty confident on that one. It was multiple things.